A look at The Veyonda Story to now

Posted on November 9th, 2021 by CEO Dr Graham Kelly

Having recently celebrated our 5th anniversary is an appropriate time to look back on the Company’s beginnings and the path to the current.

Read More

Noxopharm's Chemotherapy Program

Posted on May 10th, 2021 by CEO Dr Graham Kelly
Read More

Pandemic Treatments

Posted on April 8th, 2021 by Dr Graham Kelly

This blog is in response to a note I received this week from a shareholder. I thought it would be useful to post my reply.

'Dear Prof. Kelly

I was reading this article from the Wall Street Journal .....


....and was wondering how Veyonda would fit into this picture.'

Read More

The LuPIN Trial at St Vincent's Hospital, Sydney

Posted on February 19th, 2021 by Dr Graham Kelly

The LuPIN trial at St Vincent’s Hospital, Sydney

 Two matters were raised this week following the LuPIN data announcements at the 2021 ASCO Genitourinary Cancers Symposium. Both highly relevant.


Read More

Noxopharm's NOXCOVID-1 trial

Posted on September 11th, 2020 by Dr Graham Kelly

In a nutshell we are testing an emerging theory that an over-exuberant response of an immune function known as the STING signalling pathway is a key cause of much death and disability of COVID-19 patients and that blocking this pathway will help reduce the need for hospitalisation and reduce the severity of the COVID-19 disease.

Read More

Interpreting the recent LuPIN interim data at ASCO GU 2020

Posted on February 18th, 2020 by Dr Graham Kelly CEO

How do you interpret data from a single study using a single treatment arm? A fair question.

The answer is, cautiously. We have been cautious, and we still think the data is exciting.

Read More

A comment on 177Lu-PSMA therapy and the LuPIN study data

Posted on October 1st, 2019 by Dr Graham Kelly

177Lu-PSMA-617 (177Lu-PSMA) therapy suddenly has become a big talking point in prostate cancer circles. Delivering radiotherapy via injectable radiopharmaceuticals is being talked up as a coming mega trend in cancer therapy in general, but 177Lu-PSMA and prostate cancer is where the big story lies at the moment.

Read More

An Investment in Biotech: Part 3

Posted on September 10th, 2019 by Graham Kelly

The DARRT Program

The DARRT program aims to use Veyonda® to make radiotherapy more effective . It stands for Direct and Abscopal Response to RadioTherapy.

Read More

An Investment in Biotech: Part 2

Posted on August 23rd, 2019 by Graham Kelly

The IDX backstory (2009-2016). The birth of Noxopharm

Ironically, Noxopharm owes its existence to the failure of the OVATURE study.

Read More

An Investment in Biotech: Part 1

Posted on August 15th, 2019 by Graham Kelly

I have been meaning for some time now to write a general blog about drug development and to put the Veyonda(R)story into that context.

Read More

What you need to know about STING

Posted on July 2nd, 2019 by Dr Graham Kelly

The ‘next big thing’ comes along about every 10-15 years in oncology. The last ‘big things’ were the so-called immuno-oncology drugs (or checkpoint inhibitors) – Yervoy and Opdivo (Bristol-Myers Squibb) and Keytruda (Merck). These drugs were expected to turn cancer therapy on its head based on some early dramatic responses in patients with melanoma and lung cancer, with annual sales of US$100+ billion being projected.

Read More

Reflections on a month of progress - May 2019

Posted on June 3rd, 2019 by Dr Greg van Wyk CEO
Read More

Recent DARRT-1 interim 6-month data put into context

Posted on May 3rd, 2019 by Dr Graham Kelly
Read More

DARRT-1: Credible and Exciting

Posted on May 3rd, 2019 by Greg van Wyk, CEO
Read More

Comment on interim DARRT-1 data announced February 6, 2019

Posted on February 11th, 2019 by Blog Author

I understand the complexity around the DARRT concept, what we expect to come of the DARRT-1 study, and what the data means that we are reporting on as we move through the study. Boosting the effectiveness of radiotherapy with an immuno-oncology drug is an entirely new area of cancer therapy, so there are no yardsticks to measure us by. The only relevant yardstick is current therapeutic options and whether we can improve on them.

Read More

A Comment on IPO Returns

Posted on October 14th, 2018 by Blog Author

The stock market is on its longest bull run in modern history. The biopharma industry, in particular, is in the longest and most active financing window in its history.

Leerink Partners, a leading U.S.-based investment bank specializing in healthcare, recently published a report on the flow of public equity capital into U.S. biopharma stocks over the past 6 years, having analysed the performance[…]

Read More

Latest Appendix 4C and the CEP program

Posted on July 30th, 2018 by Blog Author

We have been asked if the Company has dropped the CEP program from our list of clinical studies as it wasn’t mentioned in the latest Appendix 4C. The answer is, no, we haven’t. But it is not a priority. We have a busy clinical program using NOX66 in combination with radiotherapy, and we anticipate the […]

Read More

CEO Blog: Timelines and Strategies

Posted on June 11th, 2018 by Blog Author

With NOX66 running in 3 separate clinical programs, there is considerable scope for priorities, commercial strategies, timelines etc to become blurred in shareholders’ minds. Hopefully this will make it clearer. …………………………………………………………………… In terms of priorities: The DARRT program in prostate cancer is #1. We regard this as our primary path to market approval and a […]

Read More